Artykuły w czasopismach na temat „Immune-related adverse effect”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Immune-related adverse effect”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Bangalore Kumar, Anagha, Alan Bryce, Prakash Vishnu, Svetomir Markovic i Marian McEvoy. "Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma". SKIN The Journal of Cutaneous Medicine 5, nr 2 (6.03.2021): 108–17. http://dx.doi.org/10.25251/skin.5.2.5.
Pełny tekst źródłaWilliams, Kiersten J., Dennis W. Grauer, David W. Henry i Michelle L. Rockey. "Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors". Journal of Oncology Pharmacy Practice 25, nr 3 (9.12.2017): 544–50. http://dx.doi.org/10.1177/1078155217744872.
Pełny tekst źródłaMuir, Christopher A., Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang i Alexander M. Menzies. "Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment". Journal of Clinical Endocrinology & Metabolism 106, nr 9 (20.04.2021): e3704-e3713. http://dx.doi.org/10.1210/clinem/dgab263.
Pełny tekst źródłaBansal, Aditi, Ankur Singla, Davinder Paul i Sukhjot Kaur. "Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect". Indian Dermatology Online Journal 14, nr 3 (2023): 391. http://dx.doi.org/10.4103/idoj.idoj_377_22.
Pełny tekst źródłaLima, Gian, Adriana Kahn, Shashank Sama i Jacqueline Savage. "Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab". Case Reports in Oncological Medicine 2019 (4.11.2019): 1–2. http://dx.doi.org/10.1155/2019/7183747.
Pełny tekst źródłaKim, Won Myung, Mun Su Park, Dong Hyun Seo, Jung Yun Lee i Jung Yoon Pyo. "Immune-related Adverse Effect after BNT162b2 Vaccination with Parallel Immune Checkpoint Inhibitor Therapy: A Case Report". Korean Journal of Medicine 98, nr 2 (1.04.2023): 93–97. http://dx.doi.org/10.3904/kjm.2023.98.2.93.
Pełny tekst źródłaBrinzevich, Daria, Virginia Falvello, Michael D. Green i Alex Bryant. "Impact of commonly prescribed medications on immune-related adverse events." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): e14704-e14704. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14704.
Pełny tekst źródłaOu, Qiyun, Yunfang Yu, Haitao Zhong, Anlin Li, Yongjian Chen, HaiYu Zhou, Shaopeng Zheng, Luyu Huang i Herui Yao. "Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e14087-e14087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14087.
Pełny tekst źródłaHamatake, Kiyonori, i Kazuaki Kojima. "Initiatives for immune-related adverse events by the outpatient pharmacist clinic". Trends in Immunotherapy 6, nr 1 (10.01.2022): 3. http://dx.doi.org/10.24294/ti.v6.i1.1385.
Pełny tekst źródłaSakai, Miho, Yuki Haga, Michiyo Kambe, Koji Nishimura, Ayako Shingyouchi, Tatsuo Miyamura, Kenji Ito i in. "A case of immune-related adverse effect diffuse gastritis induced by nivolumab". Progress of Digestive Endoscopy 98, nr 1 (25.06.2021): 91–92. http://dx.doi.org/10.11641/pde.98.1_91.
Pełny tekst źródłaMargiotta, Philip, Mario Caldararo, Daniel Altman, Sheel A. Patel, Sharon Li, Sean Clark-Garvey, Reetu Mukherji i in. "Effect of pretreatment steroids on the development of immune related adverse events." Journal of Clinical Oncology 36, nr 15_suppl (20.05.2018): e15095-e15095. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e15095.
Pełny tekst źródłaGleeson, Ferga C., Katie A. Dunleavy, Michael J. Levy, Ryan M. Carr, Mindy L. Hartgers, Lisa A. Kottschade, Robert R. McWilliams, Wen Wee Ma, Yogish C. Kudva i Aoife M. Egan. "Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events". Pancreas 53, nr 7 (sierpień 2024): e627-e629. http://dx.doi.org/10.1097/mpa.0000000000002337.
Pełny tekst źródłaElsayed, Manar, i Carrie Ye. "Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?" Journal for ImmunoTherapy of Cancer 12, nr 7 (lipiec 2024): e009309. http://dx.doi.org/10.1136/jitc-2024-009309.
Pełny tekst źródłaEl Bitar, Sandy, Chanudi Weerasinghe, Elie El-Charabaty i Marcel Odaimi. "Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy". Case Reports in Oncological Medicine 2018 (2018): 1–3. http://dx.doi.org/10.1155/2018/8408015.
Pełny tekst źródłaOsataphan, Soravis, Yu Jen Jan, Katherine A. Stafford i Prudence B. Lam. "Effect of excess weight on immune-related adverse events from immune checkpoint inhibitor in lung cancer." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e21183-e21183. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21183.
Pełny tekst źródłaRathmann, Joerg, James J. Vredenburgh, Racha Demesropian, Dorothy Wakefield, Kendra Williams, Archana Purushothaman, Jessica Bello i Latha Dulipsingh. "Cancer-immune checkpoint inhibition and autoimmune-related adverse events." Journal of Clinical Oncology 37, nr 8_suppl (10.03.2019): 107. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.107.
Pełny tekst źródłaHunting, John, Eric Olson, Andrew Thomas Faucheux, Catherine A. Elko, Mary-Peyton Knapp, Sarah Price, Stephanie Brinton i Thomas William Lycan. "Effects of pre-treatment on odds of immune-related adverse events." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): 2540. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2540.
Pełny tekst źródłaLiu, Mingyue, Xu Wang, Peng Zhang, Juanjuan Su, Xuexiang Du, Yan Zhang, Yang Liu i Pan Zheng. "813 CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (listopad 2021): A849. http://dx.doi.org/10.1136/jitc-2021-sitc2021.813.
Pełny tekst źródłaGleeson, Ferga C., Lisa Kottschade, Katie A. Dunleavy, Ryan M. Carr, Mindy Hartgers, Michael J. Levy, Wen Wee Ma, Robert McWilliams i Aoife Egan. "Tu1420 INCIDENCE AND EFFECT DURATION OF IMMUNE CHECKPOINT INHIBITOR RELATED PANCREAS ADVERSE EVENTS". Gastroenterology 164, nr 6 (maj 2023): S—1049. http://dx.doi.org/10.1016/s0016-5085(23)03438-8.
Pełny tekst źródłaCautha, Sandhya, Kevin R. Jain, Pravash Budhathoki, Tobechukwu Joseph Okobi, Tanushree Bhatt, Valentina Moirangthem, Sorab Gupta, Thanh-Ha T. Luong i Ahmad Hanif. "The study of immune-related adverse events in a community-based centre." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): 2642. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2642.
Pełny tekst źródłaZyablova, E. I., L. N. Nefedova i V. A. Porkhanov. "Radiological Imaging of Adverse Events to Immunotherapy". Journal of oncology: diagnostic radiology and radiotherapy 3, nr 3 (30.09.2020): 44–53. http://dx.doi.org/10.37174/2587-7593-2020-3-3-44-53.
Pełny tekst źródłaFragulidis, Georgios, Eirini Pantiora, Vasiliki Michalaki, Elissaios Kontis, Elias Primetis, Antonios Vezakis i Andreas Polydorou. "Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient". Journal of Oncology Pharmacy Practice 25, nr 2 (25.10.2017): 487–91. http://dx.doi.org/10.1177/1078155217738325.
Pełny tekst źródłaRai, Manoj P., Prabhjot Singh Bedi, Rohanlal Vishwanth, Fawzi Abu Rous, Shiva Shrotriya i Prajwal Dhakal. "Immune-related adverse events in melanoma: A nationwide analysis 2016." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e18253-e18253. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18253.
Pełny tekst źródłaGandhi, Shipra, Manu Pandey, Nischala Ammannagari, Chong Wang, Mark J. Bucsek, Lamya Hamad, Elizabeth Repasky i Marc S. Ernstoff. "Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors". Immunotherapy 12, nr 2 (luty 2020): 141–49. http://dx.doi.org/10.2217/imt-2019-0064.
Pełny tekst źródłaKulkarni, Ajinkya, Mrunal Kulkarni, Vinay Edlukudige Keshava, Rithikaa Ellangovan i Rajesh Thirumaran. "Awareness of immune-related adverse events among medical residents in a community hospital." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e15154-e15154. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15154.
Pełny tekst źródłaLuo, Jia, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey Kern, Donald Y. M. Leung i in. "Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 9092. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9092.
Pełny tekst źródłaShalata, Walid, Sarah Weissmann, Sapir Itzhaki Gabay, Kim Sheva, Omar Abu Saleh, Ashraf Abu Jama, Alexander Yakobson i Keren Rouvinov. "A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors". Cancers 14, nr 21 (5.11.2022): 5451. http://dx.doi.org/10.3390/cancers14215451.
Pełny tekst źródłaKhalid, Ahmed Bilal, Shadia Ibrahim Jalal i Greg Andrew Durm. "Physician awareness of immune-related adverse events from checkpoint inhibitors." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 6571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6571.
Pełny tekst źródłaKhalid, Ahmed Bilal, Shadia Ibrahim Jalal i Greg Andrew Durm. "Physician awareness of immune-related adverse events from checkpoint inhibitors." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 6571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6571.
Pełny tekst źródłaJiang, Ning, Yue Yu, Dawei Wu, Shuhang Wang, Peiwen Ma, Huilei Miao, Yu Tang i Ning Li. "Association between germ-line HLA and immune-related adverse events." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 2658. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2658.
Pełny tekst źródłaSoman, Biji, Maria Cecilia Dias, Syed Azhar J. Rizvi i Attila Kardos. "Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment". BMJ Case Reports 15, nr 12 (grudzień 2022): e251966. http://dx.doi.org/10.1136/bcr-2022-251966.
Pełny tekst źródłaInagaki, Yuichiro, Hirofumi Yokota, Yuki Takeuchi, Hitomi Sawa, Takashi Seki, Hidetoshi Akita, Mamiko Takeuchi i in. "The therapeutic effect and immune-related adverse event of nivolmab in Anjo Kosei Hospital". Annals of Oncology 30 (październik 2019): vi135. http://dx.doi.org/10.1093/annonc/mdz343.079.
Pełny tekst źródłaNakai, Masahiro, Yoshiro Kai, Kentaro Suzuki, Masayuki Matsuda, Shoma Kikukawa, Hiroyuki Masuda, Masahiro Soga i in. "A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy". Respiratory Medicine Case Reports 41 (2023): 101794. http://dx.doi.org/10.1016/j.rmcr.2022.101794.
Pełny tekst źródłaRahman, Md Mominur, Tapan Behl, Md Rezaul Islam, Md Noor Alam, Md Mohaimenul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya i Simona Gabriela Bungau. "Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer". Molecules 27, nr 12 (13.06.2022): 3798. http://dx.doi.org/10.3390/molecules27123798.
Pełny tekst źródłaChang, Michael, Nira A. Krasnow, Amy E. Blum, Vartan Pahalyants, William S. Murphy, Jaewon Yoon, Kerry Lynn Reynolds, Leah L. Thompson i Steven T. Chen. "Relationship between insurance status and diagnosis of cutaneous immune-related adverse events." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e18535-e18535. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18535.
Pełny tekst źródłaWang, Jun, Xinyue Han, Yingcui Chen, Hong Xie, Yuekai Zhang, Yu Cui i Yaping Guan. "Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): 12124. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12124.
Pełny tekst źródłaReid, Pankti, Daniel Olson i Thomas Gajewski. "Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 3066. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3066.
Pełny tekst źródłaKaszycki, Margaret A., i Jonathan Leventhal. "Review of Immune Checkpoint Inhibitors and Radiotherapy Related Skin Toxicities". Journal of Dermatology and Skin Science 3, nr 3 (20.10.2021): 10–19. http://dx.doi.org/10.29245/2767-5092/2021/3.1140.
Pełny tekst źródłaWanchoo, Rimda, Sabine Karam, Nupur N. Uppal, Valerie S. Barta, Gilbert Deray, Craig Devoe, Vincent Launay-Vacher i Kenar D. Jhaveri. "Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review". American Journal of Nephrology 45, nr 2 (2017): 160–69. http://dx.doi.org/10.1159/000455014.
Pełny tekst źródłaJamal, Shahin, Marie Hudson, Aurore Fifi-Mah i Carrie Ye. "Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist". Journal of Rheumatology 47, nr 2 (15.07.2019): 166–75. http://dx.doi.org/10.3899/jrheum.190084.
Pełny tekst źródłaNardi Agmon, Inbar, Osnat Itzhaki Ben Zadok i Ran Kornowski. "The Potential Cardiotoxicity of Immune Checkpoint Inhibitors". Journal of Clinical Medicine 11, nr 3 (7.02.2022): 865. http://dx.doi.org/10.3390/jcm11030865.
Pełny tekst źródłaShivaji, Uday N., Louisa Jeffery, Xianyong Gui, Samuel C. L. Smith, Omer F. Ahmad, Ayesha Akbar, Subrata Ghosh i Marietta Iacucci. "Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management". Therapeutic Advances in Gastroenterology 12 (styczeń 2019): 175628481988419. http://dx.doi.org/10.1177/1756284819884196.
Pełny tekst źródłaTanimura, Keiko, Tadaaki Yamada, Yusuke Chihara, Yutaka Kubota, Shinsuke Shiotsu, Takayuki Takeda, Takahiro Yamada, Osamu Hiranuma, Junji Uchino i Koichi Takayama. "The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer". Haigan 59, nr 2 (20.04.2019): 128–36. http://dx.doi.org/10.2482/haigan.59.128.
Pełny tekst źródłaAbdel-Wahab, Noha, Teresa Kus, Salah-Eddine Bentebibel, Jennifer Leigh McQuade, Isabella Claudia Glitza, Rodabe Navroze Amaria, Sapna Pradyuman Patel i in. "Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): TPS12147. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps12147.
Pełny tekst źródłaSharma, Nitika, Prashanti Atluri, Chipman Robert Geoffrey Stroud, Paul R. Walker, Sulochana Devi Cherukuri, Cynthia R. Cherry, Paul Gibbs, Teresa Parent i Jessica Hardin. "Immune related adverse events (irAEs): A unique profile based on tumor type." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e14606-e14606. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14606.
Pełny tekst źródłaNasca, Vincenzo, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, Maria Elena Elez, Marwan Fakih i in. "Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer". Journal for ImmunoTherapy of Cancer 11, nr 1 (styczeń 2023): e005493. http://dx.doi.org/10.1136/jitc-2022-005493.
Pełny tekst źródłaMooradian, Meghan, Justine Vanessa Cohen, Anita Giobbie-Hurder, Riley Fadden, Krista M. Rubin, Keith Flaherty, Don P. Lawrence i Ryan J. Sullivan. "Inflammatory arthritis: An under-recognized immune-relate adverse effect." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e14565-e14565. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14565.
Pełny tekst źródłaOren, Ohad, i Julian R. Molina. "The effect of cardiovascular disease on the association between immune-related adverse events and overall survival." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 7059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.7059.
Pełny tekst źródłaDe Bock, Marlies, Eva Hulstaert, Vibeke Kruse i Lieve Brochez. "Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review". Case Reports in Dermatology 10, nr 2 (9.08.2018): 190–97. http://dx.doi.org/10.1159/000491572.
Pełny tekst źródłaHigashiyama, Ryoko Inaba, Hidehito Horinouchi, Katsutoshi Sekine, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto i Yuichiro Ohe. "Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events." Journal of Clinical Oncology 36, nr 5_suppl (10.02.2018): 163. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.163.
Pełny tekst źródła